A pair of studies out of Japan and the United States suggest that a first-line treatment drug for type-2 diabetes could reduce the risk of developing lung cancer and colorectal cancer in smokers.
The drug metformin (sold under the brand names Glucophage, Glumetza, Riomet) has been shown to switch on an enzyme in the body that blocks a protein known as mTOR, which aids in the growth of tobacco-induced lung tumors.
CANCER TYPE(S)
Lung cancer, colorectal cancer
TREATMENT TYPE(S)
Chemoprevention
WHERE WAS THIS RESEARCH PUBLISHED?
Cancer Prevention Research
Source
Read more about this story ay Medical News Today
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
